Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. Subscribers to The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. A drug class review is now published monthly with The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The April 2012 monograph topics are on ivacaftor, vismodegib, axitinib, glucarpidase, and loxapine inhalation. The DUE/MUE is on glucarpidase.
Get full access to this article
View all access options for this article.
References
1.
Xarelto [package insert].Titusville, NJ: Janssen Pharmaceuticals Inc; November 2011.
2.
WannL.S.CurtisA.B.EllenbogenK.A.; American College of Cardiology Foundation/American Heart Association Task Force. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation.2011; 123(10): 1144–1150.
3.
FusterV.RydenL.E.CannomD.S.; American College of Cardiology Foundation/American Heart Association Task Force. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation.2011; 123(10): e269–e367.
4.
Pradaxa [package insert].Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; November 2011.
5.
Coumadin [package insert].Princeton, NJ: Bristol-Myers Squibb Company; October 2011.
6.
PerzbornE.StrassburgerJ.WilmenA.In vitro and in vivo studies of the novel antithrombotic agent BAY 59–7939 an oral, direct factor Xa inhibitor. J Thromb Haemost.2005; 3(3): 514–521.
7.
KubitzaD.BeckaM.VoithB.ZuehlsdorfM.WensingG.Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59–7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther.2005; 78(4): 412–421.
8.
GraffJ.von HentigN.MisselwitzF.Effects of oral direct factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity [published correction appears in J Clin Pharmacol. 2008; 48(11): 1368]. J Clin Pharmacol.2007; 47(11): 1398–1407.
9.
KubitzaD.BeckaM.WensingG.VoithB.ZuehlsdorfM.Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur J Clin Pharmacol.2005; 61(12): 873–880.
10.
WalengaJ.M.PrechelM.JeskeW.P.Rivaroxaban— an oral, direct factor Xa inhibitor—has potential for the management of patients with heparin-induced thrombocytopenia. Br J Haematol.2008; 143(1): 92–99.
11.
WeinzC.BuetehornU.DaehlerH.P.Pharmacokinetics of BAY 59-7939-an oral, direct factor Xa inhibitor-in rats and dogs. Xenobiotica.2005; 35(9): 891–910.
12.
MueckW.ErikssonB.I.BauerK.A.Population pharmacokinetics of rivaroxaban an oral, direct Factor Xa inhibitor in patients undergoing major orthopaedic surgery. Clin Pharmacokinet.2008; 47(3): 203–216.
13.
ZhaoX.SunP.ZhouY.Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct factor Xa inhibitor rivaroxaban in healthy Chinese subjects. Br J Clin Pharmacol.2009; 68(1): 77–88.
14.
SamamaM.M.The mechanism of action of rivaroxaban—an oral, direct factor Xa inhibitor—compared with other anticoagulants. Thrombosis Res.2011; 127(6): 497–504.
15.
MueckW.BorrisL.C.DahlO.E.Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost.2008; 100(3): 453–461.
16.
KubitzaD.BeckaM.ZuehlsdorfM.MueckW.Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59–7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol.2006; 46(5): 549–558.
17.
KubitzaD.BeckaM.ZuehlsdorfM.MueckW.Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59–7939) in healthy subjects. J Clin Pharmacol.2007; 47(2): 218–226.
18.
KubitzaD.BeckaM.RothA.MueckW.Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opinion.2008; 24(10): 2757–2765. doi: 10.1185/03007990802361499.
19.
KubitzaD.BeckaM.MueckW.Effects of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of rivaroxaban, an oral, direct factor Xa inhibitor. Br J Clin Pharmacol.2010; 70: 703–712.
20.
HalabiA.KubitzaD.ZuehlsdorfM.BeckaM.MueckW.MaatoukH.Effect of hepatic impairment on pharmacokinetics, pharmacodynamics, and tolerability of rivaroxaban, an oral, direct factor Xa inhibitor [abstract]. J Thromb Haemost.2007; 5(suppl 1): abstract P-M-635.
TurpieA.G.FisherW.D.BauerK.A.; Odi Xa-Knee Study Group. BAY 59–7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement: a phase II dose-ranging study. J Thromb Haemost.2005; 3(11): 2479–2486.
24.
ErikssonB.I.BorrisL.DahlO.E.; ODIXa-HIP Study Investigators. Oral, direct factor Xa inhibition with BAY 59–7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost.2005; 4(1): 121–128.
ROCKET AF Study Investigators.Rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: rationale and design of the ROCKET AF study. Am Heart J.2010; 159(3): 340–347.
27.
PatelM.R.; ROCKET AF Executive Steering Committee. Stroke prevention using the oral direct factor Xa inhibitor rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation (ROCKET AF) [abstract]. Circulation.2010; 122: 2217.
28.
Rivaroxaban comparable to warfarin in preventing stroke and other complications of irregular heartbeat: American Heart Association late-breaking clinical trial report [news release].Chicago, IL: American Heart Association; November 15, 2010. http://www.newsroom.heart.org/index.php?s=43&item=1191. Accessed July 13, 2011.
29.
PatelM.R.MahaffeyK.W.GargJ.; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med.2011; 365(10): 883–891.
30.
FoxK.A.A.PicciniJ.P.WojdylaD.Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J.2011; 32(19): 2387–2394.
31.
KubitzaD.MueckW.BeckaM.Randomized, double-blind, crossover study to investigate the effect of rivaroxaban on QT-interval prolongation. Drug Saf.2008; 31(1): 67–77.
32.
FisherW.D.ErikssonB.I.BauerK.A.Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies. Thromb Haemost.2007; 97(6): 931–937.
33.
ErikssonB.I.BorrisL.C.FriedmanR.J.; RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med.2008; 358(26): 2765–2775.
34.
KakkarA.K.BrennerB.DahlO.E.; RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised control trial. Lancet.2008; 372(9632): 31–39.
35.
LassenM.R.AgenoW.BorriL.C.; RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med.2008; 358(26): 2776–2786.
36.
AgnelliG.GallusA.GoldhaberS.Z.; ODIXa-DVT Study Investigators. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59–7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59–7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study. Circulation.2007; 116(2): 180–187.
37.
BullerH.R.LensingA.W.PrinsM.H.; Einstein-DVT Dose-Ranging Study. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis. The EINSTEIN-DVT Dose Ranging study. Blood.2008; 112(6): 2242–2247.
38.
KubitzaD.BeckaM.MueckW.ZuehlsdorfM.Rivaroxaban (BAY 59–7939)-an oral, direct factor Xa inhibitor-has no clinically relevant interaction with naproxen. Br J Clin Pharmacol.2007; 63(4): 469–476.
39.
KubitzaD.BeckaM.MueckW.ZuehlsdorfM.Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban-an oral, direct factor Xa inhibitor-are not affected by aspirin. J Clin Pharmacol.2006; 46(9): 981–990.
40.
Lindhoff-LastE.SamamaM.M.OrtelT.L.WeitzJ.I.SpiroT.E.Assays for measuring rivaroxaban: their suitability and limitations. Ther Drug Monit.2010; 32(6): 673–679.
41.
FreyburgerG.MacouillardG.LabroucheS.SztarkF.Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement. Thrombosis Res.2011; 127(5): 457–465.
